Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics, Inc. (GANX)
:GANX
GANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $3.19
Previous CloseN/A
Volume74.47K
Average Volume (3M)336.11K
Market Cap
$71.54M
Enterprise Value$48.60M
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$229.17K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding35,948,605
10 Day Avg. Volume392,805
30 Day Avg. Volume336,112
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue590.95
Enterprise Value/Gross Profit-764.05
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$8.00Price Target Upside302.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 1b clinical study for GT-02287 in Parkinson’s disease reached its original enrollment target ahead of schedule.
Financial SupportGain Therapeutics raised $7M from a stock and warrants offering, providing financial support into early 2026 and past key trial data releases.
Innovation And StrategyThe company's focus on innovative allosteric therapies positions it as a forward-thinking player in the biotechnology sector.
Bears Say
Financial PerformanceThe company reported a wider net loss than forecasted, primarily due to higher-than-expected operating expenses.
Risks And ChallengesRisks include, but are not limited to: delays in advancing preclinical candidates into clinical studies, unexpected safety issues, and negative trial results.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $0.95 and its highest was $3.19 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $71.54M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2025 which is in 65 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.023.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 35,948,605 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 4.795%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
Gain Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (302.01% Upside)
$8.00 (302.01% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
85.98%
12-Months-Change
Fundamentals
Return on Equity
-240.21%
Trailing 12-Months
Asset Growth
-48.77%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$8.00
▲(302.01% Upside)
Technical Analysis
Ownership Overview
3.56% Insiders
1.44% Mutual Funds
2.23% Other Institutional Investors
91.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---